SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-18-134914
Filing Date
2018-04-26
Accepted
2018-04-26 16:30:55
Documents
2
Effectiveness Date
2018-04-26

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS d549801ddefa14a.htm DEFA14A 14804
2 GRAPHIC g549801img002.jpg GRAPHIC 253735
  Complete submission text file 0001193125-18-134914.txt   365477
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38311 | Film No.: 18779012
SIC: 2836 Biological Products, (No Diagnostic Substances)